CAP Protocol for the Examination of Cystectomy Specimens
From Patients With Carcinoma of the Urinary Bladder/Treatment Effect Post
Neoadjuvant Chemotherapy (BCG not included) selections o No
known presurgical neoadjuvant therapy o Complete
response: Absence of histologically identifiable residual cancer cells and
extensive fibrosis of the tumor bed after presurgical neoadjuvant therapy
(TRG1) o Strong
response: Predominant fibrosis of the tumor bed, with residual cancer cells
occupying less than 50% of this area (TRG2) o Weak
or no response: Residual cancer cells occupying ≥50% of the tumor bed or
absence of regressive changes (TRG3) o Other
(specify): _________________ SEER Coding Instruction for Site-Specific Codes for
Neoadjuvant Therapy Treatment Effect - Schemas: All Other Schemas selections 0 Neoadjuvant therapy not given/no known
presurgical therapy 1 Complete pathological response Present: No viable cancer
cells/no residual invasive carcinoma identified Residual in situ carcinoma only 2 Near complete pathological
response Present: Single cells or rare
small groups of invasive cancer cells 3 Partial or minimal pathological response Present: Residual invasive
cancer with evident tumor regression, but more than single cells or rare small
groups of cancer cells 4 Poor or no pathological response Absent: Extensive residual
cancer with no evident tumor regression 6 Neoadjuvant therapy completed and surgical
resection performed, response not documented or unknown Cannot be determined 7 Neoadjuvant therapy completed and planned
surgical resection not performed 9 Unknown if neoadjuvant therapy performed Unknown if planned surgical
procedure performed after completion of neoadjuvant therapy
Death Certificate only (DCO) |